<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04858828</url>
  </required_header>
  <id_info>
    <org_study_id>CROC2101</org_study_id>
    <nct_id>NCT04858828</nct_id>
  </id_info>
  <brief_title>Investigation on Predictive Molecular Markers of Efficacy for Front-line Immunochemotherapy in Advanced NSCLC</brief_title>
  <official_title>Investigation on Molecular Markers Associated With the Clinical Efficacy of Immunotherapy Combined With Chemotherapy in the First-line Treatment of Patients With Advanced Non-small-cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhou Chengzhi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Institute of Respiratory Disease</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is a real-world exploratory study aiming to explore potential molecular markers&#xD;
      detectable at baseline that can enable the prediction of clinical efficacy of front-line&#xD;
      immunotherapy combined with chemotherapy in advanced non-small cell lung cancer (NSCLC). This&#xD;
      study aims to include a total of 200 treatment-naïve patients initially diagnosed with&#xD;
      advanced NSCLC. Paired tissue and blood samples collected from all patients before the start&#xD;
      of immunochemotherapy treatment (baseline) will be analyzed. The patient samples will be&#xD;
      submitted for molecular analysis, including next-generation sequencing (NGS)-based gene&#xD;
      expression profiling (GEP) and inflammation-related T-cell receptor (TCR) repertoire&#xD;
      profiling. The molecular assay results will include but will not be limited to tumor mutation&#xD;
      burden (TMB), microsatellite instability (MSI) status, DNA damage repair (DDR)-related gene&#xD;
      mutation status, and programmed death-ligand 1 (PD-L1) expression level. Patients will be&#xD;
      followed-up for treatment responses until radiological confirmation of disease progression to&#xD;
      first-line immunochemotherapy. The molecular assay results will then be analyzed with&#xD;
      clinical data including objective responses and progression-free survival outcomes, among&#xD;
      others, to identify molecular markers at baseline that are associated with clinical efficacy&#xD;
      of immunochemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Investigation on molecular markers associated with the clinical efficacy of immunotherapy combined with chemotherapy in the first-line treatment of patients with advanced non-small-cell lung cancer</measure>
    <time_frame>June 2021 - March 2024</time_frame>
    <description>Next-generation sequencing (NGS)-based gene expression profiling (GEP) and inflammation-related T-cell receptor (TCR) repertoire profiling. The molecular assay results will include but will not be limited to tumor mutation burden (TMB), microsatellite instability (MSI) status, DNA damage repair (DDR)-related gene mutation status, and programmed death-ligand 1 (PD-L1) expression level.</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Biomarkers</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with advanced NSCLC eligible for front-line treatment of immunotherapy combined&#xD;
        with chemotherapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who are clinically diagnosed with stage IV NSCLC;&#xD;
&#xD;
          2. Patients who submitted samples for molecular testing using the OncoScreen Plus panel&#xD;
             and PD-L1 (22C3) immunohistochemistry test at baseline;&#xD;
&#xD;
          3. Patients with negative results for sensitizing mutations for 6 genes, including EGFR,&#xD;
             ALK, ROS1, BRAF, MET exon 14 skipping, and RET;&#xD;
&#xD;
          4. Patients without contraindications for immunotherapy;&#xD;
&#xD;
          5. Patients who are 18 years or older at the time of signing the informed consent form;&#xD;
&#xD;
          6. Patients with life expectancy of at least 12 weeks;&#xD;
&#xD;
          7. Patients with ECOG score of 0 or 1;&#xD;
&#xD;
          8. Patients with adequate organ function defined by the following criteria:&#xD;
&#xD;
               1. Absolute neutrophil count ≥ 1.5109/L;&#xD;
&#xD;
               2. Platelets ≥ 90109/L;&#xD;
&#xD;
               3. Hemoglobin ≥ 9.0g/dL;&#xD;
&#xD;
               4. Albumin levels ≥2.8 g/L;&#xD;
&#xD;
               5. Total serum bilirubin ≤ 1.5 the upper limit of normal (ULN); for patients with&#xD;
                  liver metastases, total bilirubin ≤ 2 ULN;&#xD;
&#xD;
               6. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5&#xD;
                  ULN; for patients with liver metastases, ALT and AST ≤ 5ULN;&#xD;
&#xD;
               7. Serum creatinine ≤ 1.5 ULN;&#xD;
&#xD;
               8. International normalized ratio (INR) or plasma prothrombin time (PT) ≤1.5ULN.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with other concurrent tumors;&#xD;
&#xD;
          2. Patients with other concurrent medical conditions that may affect their follow-up and&#xD;
             short-term survival;&#xD;
&#xD;
          3. Patients with any history of immunotherapy;&#xD;
&#xD;
          4. Patients with any history of chemotherapy, radiotherapy or other anti-tumor&#xD;
             treatments;&#xD;
&#xD;
          5. Patients with heart function classified as New York Heart Association (NYHA) class III&#xD;
             or IV;&#xD;
&#xD;
          6. Patients with peripheral nerve disease;&#xD;
&#xD;
          7. Patients with confirmed hearing loss;&#xD;
&#xD;
          8. Patients with other conditions deemed unsuitable for enrollment by the researchers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Chengzhi Zhou</last_name>
    <phone>13560351186</phone>
    <email>doctorzcz@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhou Chengzhi</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chengzhi Zhou, Professor</last_name>
      <phone>13560351186</phone>
      <email>doctorzcz@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou Institute of Respiratory Disease</investigator_affiliation>
    <investigator_full_name>Zhou Chengzhi</investigator_full_name>
    <investigator_title>Chief physician</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

